MedTrace Logo

Technology Assisted Rehabilitation for Upper Limb Function in Myotonic Dystrophy Type 1

NCT05560438 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-05-14

No results posted yet for this study

Summary

Myotonic Dystrophy type 1 (DM1) is a genetic multisystem disease causing muscle weakness and myotonia. As a result, upper limb function might become impaired. There are little research regarding rehabilitation and exercise for upper limb function in DM1. It is known from research on lower limb function in DM1 and other muscular dystrophies, that there are possibilities to improve function also in these deteriorating diseases. In this single subject experimental design study, 6-10 adults with DM1, who are at an inpatient rehabilitation center, will get intensive, but personally adapted senso- and robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso. These devices have previously been used in rehabilitation research for other neurological conditions. The participants will be followed up, and evaluated at a weekly basis, using video consultations. Fine motor skill dexterity test (9HPT) and the Nut and Bolt test will be used, and active range of motion (ROM) and muscle strenght and movement of upper limb will be measured. Furthermore, patient reported outcome measures (PROMS) on hand impairment and myotonia will be used, all with purpose to evaluate upper limb function.

Conditions

  • Myotonic Dystrophy Type 1 (DM1)

Interventions

DEVICE

Tyromotion Amadeo and Armeo Senso

Robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • Vikersund Rehabilitation Center

    collaborator UNKNOWN

  • University of Oslo

    lead OTHER

Principal Investigators

  • Hilde Stendal Robinson, PhD · University of Oslo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-03
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Norway

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05560438 on ClinicalTrials.gov